Dublin, Ireland, September 15, 2014
Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that the Company has been selected to present at the Next Generation Track at BioPharm America 2014 in Boston, September 22-24, 2014.
Inflection Biosciences’ presentation will be given by Darren Cunningham, Chief Executive Officer, on Wednesday September 24 at 10.50 a.m. EDT in the Suffolk Room of the Boston Marriott Copley Place.
About BioPharm America
BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group's acclaimed European events BIO-Europe® and BIO-Europe Spring®.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises a unique dual mechanism pan-PIM/PI3 kinase inhibitor program and a pan-PIM kinase inhibitor program, both in preclinical development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. For more information please visit the Company’s website at www.inflectionbio.com